Literature DB >> 1649814

Reversal of cisplatin resistance with amphotericin B in a non-small cell lung cancer cell line.

T Morikage1, M Bungo, M Inomata, M Yoshida, T Ohmori, Y Fujiwara, K Nishio, N Saijo.   

Abstract

The potentiation of anticancer agents by non-anticancer drugs is one of the possible strategies for overcoming cellular resistance to chemotherapy. In order to overcome cis-diamminedichloroplatinum(II) (CDDP) resistance, we evaluated the sensitizing effect on CDDP-induced cytotoxicity of various non-anticancer agents which might alter membrane transport, by means of a colorimetric [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (MTT) assay. Drugs which have previously been demonstrated to modify multidrug resistance did not show a sensitizing effect to cisplatin. Only amphotericin B (AmB) selectively conquered CDDP resistance in the CDDP-resistant cell line. A drug accumulation study done by the atomic absorption method demonstrated that the accumulation of CDDP in the resistant cell line recovered to the level of the parental cell line after treatment with AmB. Thus, AmB might overcome CDDP resistance by increasing the accumulation of CDDP.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1649814      PMCID: PMC5918508          DOI: 10.1111/j.1349-7006.1991.tb01912.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


cis‐diamminedichloroplatinum(II) amphotericin B 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide phosphatebuffered saline dimethyl sulfoxide optical density drug concentration causing 50% reduction in absorbance
  25 in total

Review 1.  Non-chemotherapeutic agents that potentiate chemotherapy efficacy.

Authors:  D J Stewart; W K Evans
Journal:  Cancer Treat Rev       Date:  1989-03       Impact factor: 12.111

2.  cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells.

Authors:  P A Andrews; S Velury; S C Mann; S B Howell
Journal:  Cancer Res       Date:  1988-01-01       Impact factor: 12.701

3.  Phosphorylation of the Mr 170,000 to 180,000 glycoprotein specific to multidrug-resistant tumor cells: effects of verapamil, trifluoperazine, and phorbol esters.

Authors:  H Hamada; K Hagiwara; T Nakajima; T Tsuruo
Journal:  Cancer Res       Date:  1987-06-01       Impact factor: 12.701

4.  Glutathione-S-transferase pi as a determinant of drug resistance in transfectant cell lines.

Authors:  K Nakagawa; N Saijo; S Tsuchida; M Sakai; Y Tsunokawa; J Yokota; M Muramatsu; K Sato; M Terada; K D Tew
Journal:  J Biol Chem       Date:  1990-03-15       Impact factor: 5.157

5.  Effect of amphotericin B on Adriamycin transport in P388 cells.

Authors:  A Krishan; A Sauerteig; K Gordon
Journal:  Cancer Res       Date:  1985-09       Impact factor: 12.701

Review 6.  Resistance to cisplatin and analogues: mechanisms and potential clinical implications.

Authors:  A de Graeff; R J Slebos; S Rodenhuis
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 7.  Drugs five years later. Cisplatin.

Authors:  P J Loehrer; L H Einhorn
Journal:  Ann Intern Med       Date:  1984-05       Impact factor: 25.391

8.  In vivo characterization of combination antitumor chemotherapy with calcium channel blockers and cis-diamminedichloroplatinum(II).

Authors:  J M Onoda; K K Nelson; J D Taylor; K V Honn
Journal:  Cancer Res       Date:  1989-06-01       Impact factor: 12.701

9.  Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors.

Authors:  T Tsuruo; H Iida; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1982-11       Impact factor: 12.701

10.  Determinants of drug response in a cisplatin-resistant human lung cancer cell line.

Authors:  Y Fujiwara; Y Sugimoto; K Kasahara; M Bungo; M Yamakido; K D Tew; N Saijo
Journal:  Jpn J Cancer Res       Date:  1990-05
View more
  8 in total

1.  Amphotericin B potentiates the anticancer activity of doxorubicin on the MCF-7 breast cancer cells.

Authors:  Farzaneh Tavangar; Hamid Sepehri; Marie Saghaeian Jazi; Jahanbakhsh Asadi
Journal:  J Chem Biol       Date:  2017-06-05

2.  Modulation of resistance to cisplatin by amphotericin B and aphidicolin in human larynx carcinoma cells.

Authors:  L Beketic-Oreskovic; M Osmak
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

3.  Selective potentiation of platinum drug cytotoxicity in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines by amphotericin B.

Authors:  S Y Sharp; P Mistry; M R Valenti; A P Bryant; L R Kelland
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 4.  Cellular accumulation of the anticancer agent cisplatin: a review.

Authors:  D P Gately; S B Howell
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

5.  Reversal of cisplatin resistance by the 1,4-benzothiazepine derivative, JTV-519.

Authors:  T Nakamura; F Koizumi; N Kaneko; T Tamura; F Chiwaki; Y Koh; S Akutagawa; N Saijo; K Nishio
Journal:  Jpn J Cancer Res       Date:  2001-06

6.  Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes.

Authors:  S Y Loh; P Mistry; L R Kelland; G Abel; K R Harrap
Journal:  Br J Cancer       Date:  1992-12       Impact factor: 7.640

7.  Deleterious effect of serum proteins on the amphotericin B-induced potentiation of cisplatin in human colon cancer cells.

Authors:  M Assem; S Bonvalot; J L Beltramo; C Garrido; M T Dimanche-Boitrel; P Genne; J M Rebibou; D Caillot; B Chauffert
Journal:  Br J Cancer       Date:  1994-10       Impact factor: 7.640

8.  The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP).

Authors:  T Ohmori; T Morikage; Y Sugimoto; Y Fujiwara; K Kasahara; K Nishio; S Ohta; Y Sasaki; T Takahashi; N Saijo
Journal:  Jpn J Cancer Res       Date:  1993-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.